Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Case Material
2.2. Study Circulations
2.3. Statistical Analysis
3. Results
3.1. Inter-Observer Agreement
3.2. Distribution of Scores between Pathologists
3.3. sTILs Scores in TNBC Cases
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Savas, P.; Salgado, R.; Denkert, C.; Sotiriou, C.; Darcy, P.K.; Smyth, M.J.; Loi, S. Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat. Rev. Clin. Oncol. 2016, 13, 228–241. [Google Scholar] [CrossRef] [PubMed]
- Adams, S.; Gray, R.J.; Demaria, S.; Goldstein, L.; Perez, E.A.; Shulman, L.N.; Martino, S.; Wang, M.; Jones, V.E.; Saphner, T.J.; et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 2014, 32, 2959–2966. [Google Scholar] [CrossRef]
- Loi, S.; Michiels, S.; Salgado, R.; Sirtaine, N.; Jose, V.; Fumagalli, D.; Kellokumpu-Lehtinen, P.L.; Bono, P.; Kataja, V.; Desmedt, C.; et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann. Oncol. 2014, 25, 1544–1550. [Google Scholar] [CrossRef] [PubMed]
- Loi, S.; Sirtaine, N.; Piette, F.; Salgado, R.; Viale, G.; Van Eenoo, F.; Rouas, G.; Francis, P.; Crown, J.P.; Hitre, E.; et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 2013, 31, 860–867. [Google Scholar] [CrossRef]
- Loi, S.; Drubay, D.; Adams, S.; Pruneri, G.; Francis, P.A.; Lacroix-Triki, M.; Joensuu, H.; Dieci, M.V.; Badve, S.; Demaria, S.; et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J. Clin. Oncol. 2019, 37, 559–569. [Google Scholar] [CrossRef] [PubMed]
- Dieci, M.V.; Mathieu, M.C.; Guarneri, V.; Conte, P.; Delaloge, S.; Andre, F.; Goubar, A. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann. Oncol. 2015, 26, 1698–1704. [Google Scholar] [CrossRef]
- Denkert, C.; von Minckwitz, G.; Brase, J.C.; Sinn, B.V.; Gade, S.; Kronenwett, R.; Pfitzner, B.M.; Salat, C.; Loi, S.; Schmitt, W.D.; et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 2015, 33, 983–991. [Google Scholar] [CrossRef]
- Issa-Nummer, Y.; Darb-Esfahani, S.; Loibl, S.; Kunz, G.; Nekljudova, V.; Schrader, I.; Sinn, B.V.; Ulmer, H.U.; Kronenwett, R.; Just, M.; et al. Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer—A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS ONE 2013, 8, e79775. [Google Scholar] [CrossRef]
- Denkert, C.; von Minckwitz, G.; Darb-Esfahani, S.; Lederer, B.; Heppner, B.I.; Weber, K.E.; Budczies, J.; Huober, J.; Klauschen, F.; Furlanetto, J.; et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018, 19, 40–50. [Google Scholar] [CrossRef]
- Loi, S.; Adams, S.; Schmid, P.; Cortés, J.; Cescon, D.W.; Winer, E.P.; Toppmeyer, D.L.; Rugo, H.S.; De Laurentiis, M.; Nanda, R.; et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Ann. Oncol. 2017, 28, v608. [Google Scholar] [CrossRef]
- Burstein, H.J.; Curigliano, G.; Loibl, S.; Dubsky, P.; Gnant, M.; Poortmans, P.; Colleoni, M.; Denkert, C.; Piccart-Gebhart, M.; Regan, M.; et al. Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 2019, 30, 1541–1557. [Google Scholar] [CrossRef] [Green Version]
- Salgado, R.; Denkert, C.; Demaria, S.; Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.; Van den Eynden, G.; Baehner, F.L.; Penault-Llorca, F.; et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015, 26, 259–271. [Google Scholar] [CrossRef]
- Breast Tumours, WHO Classification of Tumours, 5th ed.; Board, International Agency for Research on Cancer: Lyon, France, 2019; Volume 2.
- Kos, Z.; Roblin, E.; Kim, R.S.; Michiels, S.; Gallas, B.D.; Chen, W.; van de Vijver, K.K.; Goel, S.; Adams, S.; Demaria, S.; et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 2020, 6, 17. [Google Scholar] [CrossRef] [PubMed]
- O’Loughlin, M.; Andreu, X.; Bianchi, S.; Chemielik, E.; Cordoba, A.; Cserni, G.; Figueiredo, P.; Floris, G.; Foschini, M.P.; Heikkilä, P.; et al. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: A multi-institutional study. Breast Cancer Res. Treat. 2018, 171, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Tramm, T.; Di Caterino, T.; Jylling, A.B.; Lelkaitis, G.; Lænkholm, A.V.; Ragó, P.; Tabor, T.P.; Talman, M.M.; Vouza, E. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: An evaluation of inter-observer agreement between pathologists. Acta Oncol. 2018, 57, 90–94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Swisher, S.K.; Wu, Y.; Castaneda, C.A.; Lyons, G.R.; Yang, F.; Tapia, C.; Wang, X.; Casavilca, S.A.; Bassett, R.; Castillo, M.; et al. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann. Surg. Oncol. 2016, 23, 2242–2248. [Google Scholar] [CrossRef]
- Denkert, C.; Wienert, S.; Poterie, A.; Loibl, S.; Budczies, J.; Badve, S.; Bago-Horvath, Z.; Bane, A.; Bedri, S.; Brock, J.; et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group. Mod. Pathol. 2016, 29, 1155–1164. [Google Scholar] [CrossRef] [PubMed]
- Kim, R.S.; Song, N.; Gavin, P.G.; Salgado, R.; Bandos, H.; Kos, Z.; Floris, G.; Eynden, G.; Badve, S.; Demaria, S.; et al. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. J. Natl. Cancer Inst. 2019, 111, 867–871. [Google Scholar] [CrossRef] [PubMed]
- Cicchetti, D.V. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol. Assess. 1994, 6, 284. [Google Scholar] [CrossRef]
- Hallgren, K.A. Computing Inter-Rater Reliability for Observational Data: An Overview and Tutorial. Tutor. Quant. Methods Psychol. 2012, 8, 23–34. [Google Scholar] [CrossRef] [Green Version]
- Koo, T.K.; Li, M.Y. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J. Chiropr. Med. 2016, 15, 155–163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pruneri, G.; Gray, K.P.; Vingiani, A.; Viale, G.; Curigliano, G.; Criscitiello, C.; Láng, I.; Ruhstaller, T.; Gianni, L.; Goldhirsch, A.; et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res. Treat. 2016, 158, 323–331. [Google Scholar] [CrossRef] [PubMed]
- Park, J.H.; Jonas, S.F.; Bataillon, G.; Criscitiello, C.; Salgado, R.; Loi, S.; Viale, G.; Lee, H.J.; Dieci, M.V.; Kim, S.B.; et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann. Oncol. 2019, 30, 1941–1949. [Google Scholar] [CrossRef]
- Deman, F.; Punie, K.; Laenen, A.; Neven, P.; Oldenburger, E.; Smeets, A.; Nevelsteen, I.; Van Ongeval, C.; Baten, A.; Faes, T.; et al. Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. Breast Cancer Res. Treat. 2020, 184, 985–998. [Google Scholar] [CrossRef] [PubMed]
- Klauschen, F.; Müller, K.R.; Binder, A.; Bockmayr, M.; Hägele, M.; Seegerer, P.; Wienert, S.; Pruneri, G.; de Maria, S.; Badve, S.; et al. Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Semin. Cancer Biol. 2018, 52 Pt 2, 151–157. [Google Scholar] [CrossRef] [Green Version]
- Nawaz, S.; Heindl, A.; Koelble, K.; Yuan, Y. Beyond immune density: Critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod. Pathol. 2015, 28, 766–777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heindl, A.; Sestak, I.; Naidoo, K.; Cuzick, J.; Dowsett, M.; Yuan, Y. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. J. Natl. Cancer Inst. 2018, 110, 166–175. [Google Scholar] [CrossRef]
- Le, H.; Gupta, R.; Hou, L.; Abousamra, S.; Fassler, D.; Torre-Healy, L.; Moffitt, R.A.; Kurc, T.; Samaras, D.; Batiste, R.; et al. Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer. Am. J. Pathol. 2020, 190, 1491–1504. [Google Scholar] [CrossRef] [Green Version]
- Polley, M.Y.; Leung, S.C.; Gao, D.; Mastropasqua, M.G.; Zabaglo, L.A.; Bartlett, J.M.; McShane, L.M.; Enos, R.A.; Badve, S.S.; Bane, A.L.; et al. An international study to increase concordance in Ki67 scoring. Mod. Pathol. 2015, 28, 778–786. [Google Scholar] [CrossRef] [Green Version]
- Nielsen, T.O.; Leung, S.; Rimm, D.L.; Dodson, A.; Acs, B.; Badve, S.; Denkert, C.; Ellis, M.J.; Fineberg, S.; Flowers, M.; et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 2020. [CrossRef]
- Rakha, E.A.; Bennett, R.L.; Coleman, D.; Pinder, S.E.; Ellis, I.O.; UK National Coordinating Committee for Breast Pathology (EQA Scheme Steering Committee). Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. J. Clin. Pathol. 2017, 70, 51–57. [Google Scholar] [CrossRef]
- Dieci, M.V.; Criscitiello, C.; Goubar, A.; Viale, G.; Conte, P.; Guarneri, V.; Ficarra, G.; Mathieu, M.C.; Delaloge, S.; Curigliano, G.; et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann. Oncol. 2014, 25, 611–618. [Google Scholar] [CrossRef] [PubMed]
- Luen, S.J.; Salgado, R.; Dieci, M.V.; Vingiani, A.; Curigliano, G.; Gould, R.E.; Castaneda, C.; D’Alfonso, T.; Sanchez, J.; Cheng, E.; et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann. Oncol. 2019, 30, 236–242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamy, A.S.; Bonsang-Kitzis, H.; De Croze, D.; Laas, E.; Darrigues, L.; Topciu, L.; Menet, E.; Vincent-Salomon, A.; Lerebours, F.; Pierga, J.Y.; et al. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Clin. Cancer Res. 2019, 25, 6731–6741. [Google Scholar] [CrossRef] [Green Version]
- Tőkés, A.M.; Rusz, O.; Cserni, G.; Tóth, E.; Rubovszky, G.; Tőkés, T.; Vízkeleti, L.; Reiniger, L.; Kószó, R.; Kahán, Z.; et al. Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer. Acta Oncol. 2019, 58, 1603–1611. [Google Scholar] [CrossRef] [PubMed]
- Schmid, P.; Salgado, R.; Park, Y.H.; Muñoz-Couselo, E.; Kim, S.B.; Sohn, J.; Im, S.A.; Foukakis, T.; Kuemmel, S.; Dent, R.; et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann. Oncol. 2020, 31, 569–581. [Google Scholar] [CrossRef] [PubMed]
- Bassez, A.; Vos, H.; Van Dyck, L.; Floris, G.; Arijs, I.; Desmedt, C.; Boeckx, B.; Vanden Bempt, M.; Nevelsteen, I.; Lambein, K.; et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 2021, 27, 820–832. [Google Scholar] [CrossRef] [PubMed]
sTILs | Circulation 1 a (n = 23) | Circulation 1 a (n = 14) | Circulation 2 (n = 14) | ||||||
---|---|---|---|---|---|---|---|---|---|
(%) | ICC | 95% CI | p Value | ICC | 95% CI | p Value | ICC | 95% CI | p Value b |
Absolute values | |||||||||
0.634 | 0.539–0.735 | <0.001 | 0.662 | 0.566–0.760 | <0.001 | 0.798 | 0.727–0.864 | <0.001 | |
Cutpoints | |||||||||
≥10 ≥20 | 0.368 0.484 | 0.278–0.488 0.385–0.603 | <0.001 <0.001 | 0.426 0.492 | 0.324–0.551 0.388–0.614 | <0.001 <0.001 | 0.486 0.657 | 0.382–0.608 0.561–0.756 | <0.001 <0.001 |
≥25 | 0.573 | 0.475–0.684 | <0.001 | 0.602 | 0.501–0.711 | <0.001 | 0.596 | 0.495–0.706 | <0.001 |
≥30 | 0.537 | 0.438–0.652 | <0.001 | 0.555 | 0.451–0.671 | <0.001 | 0.597 | 0.495–0.706 | <0.001 |
≥40 | 0.488 | 0.389–0.606 | <0.001 | 0.506 | 0.401–0.626 | <0.001 | 0.644 | 0.546–0.745 | <0.001 |
≥50 | 0.428 | 0.332–0.549 | <0.001 | 0.440 | 0.337–0.564 | <0.001 | 0.569 | 0.465–0.682 | <0.001 |
≥60 | 0.351 | 0.263–0.470 | <0.001 | 0.368 | 0.271–0.493 | <0.001 | 0.479 | 0.375–0.602 | <0.001 |
sTILs | n (%) a | Cutpoint | n (%) a |
---|---|---|---|
Cutpoint | |||
<20% | 27 (55) | ≥20% | 22 (45) |
<25% | 34 (69) | ≥25% | 15 (31) |
<30% | 35 (71) | ≥30% | 14 (29) |
<40% | 40 (82) | ≥40% | 9 (18) |
<50% | 44 (90) | ≥50% | 5 (10) |
<60% | 46 (94) | ≥60% | 3 (6) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kilmartin, D.; O’Loughlin, M.; Andreu, X.; Bagó-Horváth, Z.; Bianchi, S.; Chmielik, E.; Cserni, G.; Figueiredo, P.; Floris, G.; Foschini, M.P.; et al. Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers 2021, 13, 4410. https://doi.org/10.3390/cancers13174410
Kilmartin D, O’Loughlin M, Andreu X, Bagó-Horváth Z, Bianchi S, Chmielik E, Cserni G, Figueiredo P, Floris G, Foschini MP, et al. Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers. 2021; 13(17):4410. https://doi.org/10.3390/cancers13174410
Chicago/Turabian StyleKilmartin, Darren, Mark O’Loughlin, Xavier Andreu, Zsuzsanna Bagó-Horváth, Simonetta Bianchi, Ewa Chmielik, Gábor Cserni, Paulo Figueiredo, Giuseppe Floris, Maria Pia Foschini, and et al. 2021. "Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer" Cancers 13, no. 17: 4410. https://doi.org/10.3390/cancers13174410
APA StyleKilmartin, D., O’Loughlin, M., Andreu, X., Bagó-Horváth, Z., Bianchi, S., Chmielik, E., Cserni, G., Figueiredo, P., Floris, G., Foschini, M. P., Kovács, A., Heikkilä, P., Kulka, J., Laenkholm, A.-V., Liepniece-Karele, I., Marchiò, C., Provenzano, E., Regitnig, P., Reiner, A., ... Callagy, G. (2021). Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers, 13(17), 4410. https://doi.org/10.3390/cancers13174410